CompanyGraphAt a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.31B, above the global median of $1.18B
- FinancialsAltman Z-Score 7.81: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.18%
Annual Rate
CNY 0.48Paid semi-annual
Payout Ratio
52.3%Sustainable
Payback Period
64.1 yr
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.79BCNY1.31B · vs all stocks (USD)
Trailing P/E
32.83xvs Medical Devices peers
Revenue (TTM)
1.49BCNY221.86M · vs all stocks (USD)
Profit Margin
17.42%vs Medical Devices peers
Beta
0.1700xvs all stocks
52-Week Change
-34.39%vs all stocks
Forward Annual Dividend Yield
2.18%vs all stocks
Market Capitalization
8.79BCNY1.31B · vs all stocks (USD)
Enterprise Value
5.62BCNY838.54M · vs all stocks (USD)
Trailing P/E
32.83xvs Medical Devices peers
Forward P/E
22.89xvs Medical Devices peers
Price to Sales (TTM)
5.74xvs Medical Devices peers
Price to Book (MRQ)
2.02xvs Medical Devices peers
Enterprise to Revenue
3.78xvs Medical Devices peers
Enterprise to EBITDA
18.14xvs Medical Devices peers
Gross Margin
65.82%vs Medical Devices peers
Profit Margin
17.42%vs Medical Devices peers
Operating Margin
23.67%vs Medical Devices peers
Return on Assets (TTM)
3.24%vs Medical Devices peers
Return on Equity (TTM)
6.30%vs Medical Devices peers
Revenue (TTM)
1.49BCNY221.86M · vs all stocks (USD)
Revenue per Share (TTM)
3.79CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-9.50%vs Medical Devices peers
Gross Profit (TTM)
928.38MCNY138.58M · vs all stocks (USD)
EBITDA (TTM)
334.24MCNY49.89M · vs all stocks (USD)
Net Income (TTM)
258.92MCNY38.65M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.40%vs Medical Devices peers
Operating Cash Flow (TTM)
369.62MCNY55.17M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
255.06MCNY38.07M · vs all stocks (USD)
Forward Annual Dividend Rate
0.4800CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
2.18%vs all stocks
Trailing Annual Dividend Rate
0.3400CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.55%vs all stocks
Payout Ratio
52.31%vs Medical Devices peers
Minority Interest (Equity)
14.89MCNYFY2025 · Dec 31, 2025Revenue
1.52BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
534.83MCNYFY2025 · Dec 31, 2025Gross Profit
987.96MCNYFY2025 · Dec 31, 2025Operating Income
321.10MCNY47.93M · vs all stocks (USD)
Pre-tax Income
324.07MCNYFY2025 · Dec 31, 2025Income Tax Expense
50.26MCNYFY2025 · Dec 31, 2025Net Income
273.80MCNYFY2025 · Dec 31, 2025EBIT
325.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
430.16MCNYFY2025 · Dec 31, 2025Research & Development
112.30MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
315.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
22.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
15.24MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
975.39KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
273.80MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-5.16MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
275.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
263.19MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.25BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
273.80MCNYFY2025 · Dec 31, 2025Other Non-cash Items
50.05MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-65.35MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
17.13MCNYFY2025 · Dec 31, 2025Capital Expenditures
-12.44MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.99BCNYFY2025 · Dec 31, 2025Sale of Investments
4.38BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-618.18MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-127.69MCNYFY2025 · Dec 31, 2025Other Financing Charges
-112.31MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-239.99MCNYFY2025 · Dec 31, 2025Shares Outstanding
400.00MSharesUpdated Sep 22, 2026Float Shares
70.50MSharesUpdated Sep 22, 2026% Held by Insiders
84.85%vs all stocks
% Held by Institutions
1.04%vs all stocks
Total Cash (MRQ)
2.91BCNY434.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.33CNYUpdated Sep 22, 2026Total Debt (MRQ)
19.28MCNY2.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0046xvs Medical Devices peers
Current Ratio (MRQ)
4.32xvs Medical Devices peers
Book Value per Share (MRQ)
10.56CNYUpdated Sep 22, 2026Total Assets
5.06BCNY755.46M · vs all stocks (USD)
Total Current Assets
4.31BCNYFY2025 · Dec 31, 2025Total Liabilities
901.67MCNYFY2025 · Dec 31, 2025Total Non-current Assets
752.63MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
863.31MCNYFY2025 · Dec 31, 2025Cash
1.25BCNYFY2025 · Dec 31, 2025Cash Equivalents
127.04MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.37BCNYFY2025 · Dec 31, 2025Other Short-term Investments
306.15MCNYFY2025 · Dec 31, 2025Accounts Receivable
288.88MCNYFY2025 · Dec 31, 2025Inventory
589.30MCNYFY2025 · Dec 31, 2025Accounts Payable
283.16MCNYFY2025 · Dec 31, 2025Short-term Debt
29.38MCNYFY2025 · Dec 31, 2025Other Current Liabilities
77.14MCNYFY2025 · Dec 31, 2025Long-term Debt
8.56MCNYFY2025 · Dec 31, 2025Common Stock (Book)
400.00MCNYFY2025 · Dec 31, 2025Retained Earnings
2.28BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.16BCNY620.87M · vs all stocks (USD)
Treasury Stock
80.01MCNYFY2025 · Dec 31, 202552-Week Low
19.83CNYUpdated Sep 22, 202652-Week High
34.46CNYUpdated Sep 22, 202652-Week Change
-34.39%vs all stocks
Beta
0.1700xvs all stocks
50-Day MA
21.79CNYUpdated Sep 22, 2026200-Day MA
26.45CNYUpdated Sep 22, 2026Avg 10-Day Volume
1.38MSharesUpdated Sep 22, 2026Avg 30-Day Volume
1.30MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.6500CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.81: safe zoneNotable
Altman Z-Score: 7.81
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.31B, above the global median of $1.18BNotable
Market cap (USD): 1,312,381,840Global Median: 1,180,223,658.953
Levered free cash flow is $38.07M, above the global median of $18.73MNotable
Levered free cash flow (USD): 38,072,199.567Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
JYP Entertainment Corporation
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And Equity
VT Co., Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And Equity
Ghcl Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And Equity